Patra NeurosurgicalPatient education

Procedure

Stereotactic radiosurgery

A precise, high dose of radiation aimed at a small target in the brain. Despite the name, there is no cut. It aims to stop a tumor from growing, not to remove it.

How this page was written
Compiled from the sources cited on the page, with AI drafting assistance
Clinical review
Not individually reviewed by a clinician. How pages are written
Last updated
November 17, 2026

General information, not medical advice. In an emergency call 911. Full disclaimer

What it does

Stereotactic radiosurgery (SRS) is not open surgery. There is no cut. It aims many beams of radiation at a small target so that the target gets a high dose and nearby brain gets much less. It is given in one session or in a few (up to about 5). [1]

SRS can be given by a machine that uses gamma rays or by a linear accelerator, which makes x-rays. Proton beams are used in a few places. [1]

The goal is to control the tumor, not to remove it. The radiation can shrink the tumor or slow its growth. [2]

When it is considered

What matters most in the decision

Compared with whole-brain radiation. In a trial of 213 people with 1 to 3 brain metastases, adding whole-brain radiation to SRS lowered the chance of new brain tumors. But thinking got worse by 3 months in about 92 out of 100 with both treatments, compared with about 64 out of 100 with SRS alone. Survival was similar. [6] After a tumor was removed, another trial found less decline in thinking with SRS to the spot than with whole-brain radiation, with similar survival. [7]

Compared with surgery. Surgery is more likely to help when a large tumor presses on the brain. [3] For a vestibular schwannoma pressing on the brainstem, surgery is the main treatment. [5]

Compared with watching. For a small vestibular schwannoma, watching with yearly MRI scans is weighed against SRS. [5]

Preparation and what happens

Expected benefits

Brain metastases. In a review of 17 studies, the treated tumor was controlled at 1 year in about 83 to 88 out of 100 tumors. [8] After a tumor was removed, SRS to the spot raised the share free of regrowth there at 1 year from about 43 out of 100 to about 72 out of 100. [9]

Vestibular schwannoma. [5]

Risks and complications

Short-term effects. Early tiredness is common and usually fades within weeks. Headaches can happen. The pin sites from a head frame may bleed a little. [1]

Radiation necrosis. This is damage to brain tissue from the radiation. It can cause swelling and symptoms months later. In a review of 52 studies of brain metastases, it happened in about 7 out of 100 people. [10] For melanoma, it may be more common when SRS is combined with immunotherapy drugs, about 16 out of 100 compared with about 7 out of 100, though this difference was not certain. [11]

Other side effects. In a study of 1,194 people with brain metastases, about 8 out of 100 had a side effect from SRS. About 2 to 3 out of 100 had a serious one. [4]

New tumors. SRS treats only the tumors it targets. New brain metastases can appear later. [6]

Long-term risks. Late effects are rare but can be permanent. There is a slight long-term risk of a new cancer from radiation. [1] For vestibular schwannoma, one study found no tumors caused by radiation over more than 11,000 years of combined patient follow-up. [5]

Alternatives

Recovery and follow-up

Most people go home the same day and return to normal activities in 1 or 2 days. [1] You will have regular checkups with your radiation doctor. [1] For a vestibular schwannoma, experts advise MRI and a hearing test each year for 5 years after SRS. [5] Recovery varies. Follow the discharge instructions from your own team.

Questions to ask

  1. What is the goal of SRS for my tumor: control, not removal?
  2. Will I have one session or several?
  3. What is my risk of radiation necrosis, and how would you treat it?
  4. How does SRS compare with surgery or watching in my case?
  5. How often will I need MRI scans afterward?

Sources

  1. Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiotherapy (SBRT). RadiologyInfo.org, Radiological Society of North America and American College of Radiology. Published May 1, 2023. Open source
  2. Vestibular Schwannoma (Acoustic Neuroma) and Neurofibromatosis. National Institute on Deafness and Other Communication Disorders. Published March 6, 2017. Open source
  3. Vogelbaum MA, Brown PD, Messersmith H, et al. Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol. 2022;40(5):492-516. Published December 21, 2021. Open source
  4. Yamamoto M, Serizawa T, Shuto T, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014;15(4):387-395. Published March 10, 2014. Open source
  5. Goldbrunner R, Weller M, Regis J, et al. EANO guideline on the diagnosis and treatment of vestibular schwannoma. Neuro Oncol. 2020;22(1):31-45. Published January 11, 2020. Open source
  6. Brown PD, Jaeckle K, Ballman KV, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA. 2016;316(4):401-409. Published July 26, 2016. Open source
  7. Brown PD, Ballman KV, Cerhan JH, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18(8):1049-1060. Published July 4, 2017. Open source
  8. Singh R, Roubil JG, Lehrer EJ, et al. The impact of margin expansions on local control and radionecrosis following stereotactic radiosurgery for brain metastases: a systematic review and meta-analysis. Pract Radiat Oncol. 2025;15(3):e245-e257. Published February 13, 2025. Open source
  9. Mahajan A, Ahmed S, McAleer MF, et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18(8):1040-1048. Published July 4, 2017. Open source
  10. Walker HB, Casey K, Ricci S, et al. A systematic review and meta-analysis of radiation necrosis incidence in brain metastasis treated by Gamma Knife and CyberKnife stereotactic radiosurgery. World Neurosurg. 2025;202:124390. Published August 20, 2025. Open source
  11. Kim PH, Suh CH, Kim HS, et al. Immune checkpoint inhibitor therapy may increase the incidence of treatment-related necrosis after stereotactic radiosurgery for brain metastases: a systematic review and meta-analysis. Eur Radiol. 2021;31(6):4114-4129. Published November 25, 2020. Open source